NCT04328727View on ClinicalTrials.gov

Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 4, 2020

Primary Completion Date

June 10, 2022

Study Completion Date

December 6, 2024

Conditions
Severe Aplastic Anemia (SAA)
Interventions
DRUG

eltrombopag

Tablet 25mg and 12.5mg

DRUG

rabbit anti-thymocyte globulin (r-ATG)

r-ATG 25 mg sterile lyophilized powder in 10 mL vials for IV use

DRUG

cyclosporine A (CsA)

CsA 25mg Capsule or CsA 5.0g/50mL solution for oral use

Trial Locations (12)

83301

Novartis Investigative Site, Kaohsiung City

130021

Novartis Investigative Site, Changchun

300020

Novartis Investigative Site, Tianjin

300052

Novartis Investigative Site, Tianjin

330006

Novartis Investigative Site, Nanchang

450052

Novartis Investigative Site, Zhengzhou

510000

Novartis Investigative Site, Guangzhou

466 8560

Novartis Investigative Site, Nagoya

812-8582

Novartis Investigative Site, Fukuoka

104 8560

Novartis Investigative Site, Chuo Ku

03080

Novartis Investigative Site, Seoul

06351

Novartis Investigative Site, Seoul

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY